Arvinas (ARVN) Equity Income (2019 - 2020)

Arvinas' (ARVN) quarterly Equity Income came in at -$1.4 million in Q2 2020, down 227.27% quarter-over-quarter from $1.1 million in Q1 2020.

Arvinas (ARVN) Equity Income (2019 - 2020) Analysis & Trends

Arvinas' Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2020.

On a quarterly basis, Equity Income changed N/A year-over-year to -$1.4 million in Q2 2020; TTM through Jun 2020 was $49.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $49.8 million, changed N/A from the prior year.
Equity Income retreated to -$1.4 million in Q2 2020 per ARVN's latest filing, from $1.1 million in the prior quarter.
Across five years, Equity Income topped out at $99.3 million in Q4 2019 and bottomed at -$49.5 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Arvinas	519.68 Mn	-95.22 Mn	-	-

Download Data